The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes

Description

This study will evalute the effect of a low glycemic load (LGL diet on dysglycemia, insulin requirements, DXA-derived body composition, gastrointestinal symptoms and quality of life measures in adults with cystic fibrosis-related diabetes (CFRD). We will use continuous glucose monitors (CGM) to assess the LGL diet both in a controlled setting (via a meal delivery company) and in free-living conditions.

Conditions

Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis With Intestinal Manifestations

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will evalute the effect of a low glycemic load (LGL diet on dysglycemia, insulin requirements, DXA-derived body composition, gastrointestinal symptoms and quality of life measures in adults with cystic fibrosis-related diabetes (CFRD). We will use continuous glucose monitors (CGM) to assess the LGL diet both in a controlled setting (via a meal delivery company) and in free-living conditions.

The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes

The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes

Condition
Cystic Fibrosis
Intervention / Treatment

-

Contacts and Locations

Boston

Boston Children's Hospital, Boston, Massachusetts, United States, 02115

Providence

Rhode Island Hospital, Providence, Rhode Island, United States, 02903

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 years and above
  • * Genetically confirmed diagnosis of CF
  • * Diagnosis of pancreatic insufficiency, requiring pancreatic enzyme replacement
  • * Criteria for CFRD:
  • * FEV1 \<50% predicted on most recent pulmonary function testing
  • * BMI \<18 kg/m2
  • * Currently receiving enteral nutrition support via GT feeds
  • * Pregnancy, plan to become pregnant in the next 3-months, or sexually active without use of contraception
  • * Use of IV antibiotics or systemic supraphysiologic glucocorticoids for CF exacerbation within 1 month
  • * Started or stopped treatment with a CFTR modulator within 3 months of enrollment
  • * Currently adhering to an LGL or other carbohydrate-restricted diet (carbohydrate intake \<30% of total daily caloric intake)

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Rhode Island Hospital,

Kevin J Scully, MB BCh BAO, PRINCIPAL_INVESTIGATOR, Rhode Island Hospital

Melissa S Putman, MD, MSc, PRINCIPAL_INVESTIGATOR, Boston Children's Hospital

Study Record Dates

2025-07-01